At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- ADP adoptive cell therapy (biological)
- How long the study runs
- Study runs about 168 months (dates as stated)
- About the drug or intervention
- ADP adoptive cell therapy — biological: No study drug is administered in this study.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- Not specified
- Who
- All
- Number of participants
- 250
- Started
- 2018-04-09
- Last checked
- 2026-02
Plain English Summary
What is this study?
- • Testing a new treatment for neoplasms
- • Phase1 - 250 participants
- • This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion
Who can take part?
- • Adults
- • Diagnosed with neoplasms
Where?
- • London - University College London Hospitals NHS Foundation Trust
- • Manchester - USWM CT Investigational Site
- • Sutton - The Royal Marsden NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
More detail
Participants who received a ADP adoptive cell therapy will be enrolled in this non-therapeutic, multi-center, long term follow-up (LTFU) study and will be followed for up to 15 years post-infusion of lentiviral vector-based adoptive cell therapy. Participants will be monitored for safety following last adoptive cell therapy infusion.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: Not specified
- Who can join: All genders
What the study is looking for
- ✓Participants who have received at least one dose of ADP adoptive cell therapy agent.
- ✓Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
- ✓Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
- ✓Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception...
- ✓The investigator is responsible for review of medical history.
Who cannot take part
- ✗\- None
See the full criteria
Where Is This Study? (3 UK sites)
University College London Hospitals NHS Foundation Trust
London NW1 2PG, United Kingdom
Rajinder Sidhu - Associate Director, Research Governance and Operations
uclh.jro-communications@nhs.net020 3447 9825USWM CT Investigational Site
Manchester M20 4BX, United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton SM2 5PT, United Kingdom